Ernexa Therapeutics (ERNA) Stock Jumps Over 78% as Q1 Loss Narrows

TLDR

• Ernexa Therapeutics posted a Q1 2026 net loss of $5.51M, down from $8.20M in Q1 2025.
• Diluted loss per share improved to $(6.95) from $(57.76) a year ago.
• The company ended Q1 with $9.2M cash, boosted by a $10.5M February public offering.
• Lead candidate ERNA-101 showed tumor clearance and 100% long-term survival in preclinical studies when combined with PD-1 therapy.
• Ernexa completed a 1-for-25 reverse stock split in May and filed a $50M shelf registration with an ATM program to address future cash needs.

---

Ernexa Therapeutics (ERNA) reported first-quarter 2026 results on May 11, with the stock surging over 78% on the day. The preclinical cell therapy company narrowed its net loss and gave investors an update on its pipeline.

Ernexa Therapeutics Inc., ERNA

The company posted a net loss of $5.51 million for Q1 2026, compared to a $8.20 million loss in the same period last year. That’s a $2.70 million improvement year-over-year.

Diluted loss per share came in at $(6.95), a sharp improvement from $(57.76) in Q1 2025. The year-ago figure reflects the pre-split share count, following Ernexa’s 1-for-25 reverse stock split which took effect May 4, 2026.

Operating expenses for the quarter totalled $5.6 million. That included $1.9 million in research and development costs, $1.6 million in general and administrative expenses, and a $2.0 million goodwill impairment charge.

Ernexa ended the quarter with $9.2 million in cash. That was helped by a February public offering that raised approximately $10.5 million in gross proceeds through common stock, pre-funded warrants, and milestone warrants.

Management flagged that April 30 cash of around $8.3 million falls below what the company expects to need over the next 12 months.

To bridge that gap, Ernexa filed a $50 million universal shelf registration and set up an at-the-market (ATM) program, through which it expects access to up to $9.2 million.

ERNA-101 Shows Early Promise

On the pipeline side, ERNA-101, the company’s lead oncology candidate, showed tumor growth reduction in preclinical models. When combined with PD-1 therapy, it produced tumor clearance and 100% long-term survival in the reported studies.

Those are preclinical results — the real test comes in humans. Ernexa says it completed a pre-IND meeting with the FDA and plans to submit an IND application later in 2026, with a Phase I investigator-sponsored trial targeted for H2 2026.

The company is also advancing ERNA-201, an IL-10-secreting iMSC therapy for autoimmune conditions, and is pursuing strategic partnerships and grants to support development.

Japan Expansion and Compliance Steps

Beyond the pipeline, Ernexa was accepted into a Japan trade acceleration program aimed at supporting market entry in that country.

The reverse stock split, which left 1,166,333 common shares outstanding as of May 8, 2026, was partly a compliance move. Ernexa expects it will help the company regain Nasdaq bid-price compliance.

As of March 31, 2026, the company had 1,166,333 common shares outstanding after the split was applied retroactively.

The post Ernexa Therapeutics (ERNA) Stock Jumps Over 78% as Q1 Loss Narrows appeared first on CoinCentral.